Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy : Perspectives From the Treasure Database
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This study aimed to investigate bDMARD preferences of physicians when treating of rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients with a history of malignancy.
METHODS: The data for this cross-sectional study were gathered from the TReasure database using a date range of December 2017 and January 2020. Biological disease-modifying antirheumatic drug preferences were analyzed for 40 RA patients and 25 SpA patients with a history of malignancy.
RESULTS: The most frequently prescribed bDMARD was rituximab, which was given to 28 RA patients (70%). For 25 patients (62.5%), the time between the diagnosis of malignancy and starting on a bDMARD regimen was less than 60 months, with a median interval of 43.5 months. Among SpA patients, the preferred bDMARDs were secukinumab and etanercept, which were each administered to 7 patients (28%). For 13 SpA patients (52%), the time between the diagnosis of malignancy and starting on bDMARDs was less than 60 months, with a median interval of 97 months.
CONCLUSIONS: The observed bDMARD preferences may be related to the therapeutic effects of rituximab on lymphoproliferative malignancies, the protective effects of secukinumab on tumor progression, and the short half-life of etanercept. Biological disease-modifying antirheumatic drugs should be used in RA and SpA patients with malignancy in case of high inflammatory activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases - 28(2022), 2 vom: 01. März, Seite e318-e323 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tekgoz, Emre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.02.2022 Date Revised 27.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/RHU.0000000000001699 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325635501 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325635501 | ||
| 003 | DE-627 | ||
| 005 | 20231225192845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/RHU.0000000000001699 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325635501 | ||
| 035 | |a (NLM)34014053 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tekgoz, Emre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy |b Perspectives From the Treasure Database |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2022 | ||
| 500 | |a Date Revised 27.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This study aimed to investigate bDMARD preferences of physicians when treating of rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients with a history of malignancy | ||
| 520 | |a METHODS: The data for this cross-sectional study were gathered from the TReasure database using a date range of December 2017 and January 2020. Biological disease-modifying antirheumatic drug preferences were analyzed for 40 RA patients and 25 SpA patients with a history of malignancy | ||
| 520 | |a RESULTS: The most frequently prescribed bDMARD was rituximab, which was given to 28 RA patients (70%). For 25 patients (62.5%), the time between the diagnosis of malignancy and starting on a bDMARD regimen was less than 60 months, with a median interval of 43.5 months. Among SpA patients, the preferred bDMARDs were secukinumab and etanercept, which were each administered to 7 patients (28%). For 13 SpA patients (52%), the time between the diagnosis of malignancy and starting on bDMARDs was less than 60 months, with a median interval of 97 months | ||
| 520 | |a CONCLUSIONS: The observed bDMARD preferences may be related to the therapeutic effects of rituximab on lymphoproliferative malignancies, the protective effects of secukinumab on tumor progression, and the short half-life of etanercept. Biological disease-modifying antirheumatic drugs should be used in RA and SpA patients with malignancy in case of high inflammatory activity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Colak, Seda |e verfasserin |4 aut | |
| 700 | 1 | |a Yardimci, Kubra G |e verfasserin |4 aut | |
| 700 | 1 | |a Kucuksahin, Orhan |e verfasserin |4 aut | |
| 700 | 1 | |a Cinar, Muhammet |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Sedat |e verfasserin |4 aut | |
| 700 | 1 | |a Kasifoglu, Timucin |e verfasserin |4 aut | |
| 700 | 1 | |a Bes, Cemal |e verfasserin |4 aut | |
| 700 | 1 | |a Yagiz, Burcu |e verfasserin |4 aut | |
| 700 | 1 | |a Erden, Abdulsamet |e verfasserin |4 aut | |
| 700 | 1 | |a Kilic, Levent |e verfasserin |4 aut | |
| 700 | 1 | |a Kanitez, Nilufer A |e verfasserin |4 aut | |
| 700 | 1 | |a Ertenli, Ali I |e verfasserin |4 aut | |
| 700 | 1 | |a Coskun, Belkis N |e verfasserin |4 aut | |
| 700 | 1 | |a Ediboglu, Elif D |e verfasserin |4 aut | |
| 700 | 1 | |a Mercan, Ridvan |e verfasserin |4 aut | |
| 700 | 1 | |a Kiraz, Sedat |e verfasserin |4 aut | |
| 700 | 1 | |a Yazisiz, Veli |e verfasserin |4 aut | |
| 700 | 1 | |a Karadag, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Atagunduz, Pamir |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyoncu, Umut |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases |d 1995 |g 28(2022), 2 vom: 01. März, Seite e318-e323 |w (DE-627)NLM094595941 |x 1536-7355 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:2 |g day:01 |g month:03 |g pages:e318-e323 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/RHU.0000000000001699 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 2 |b 01 |c 03 |h e318-e323 | ||